Patent intelligence · US
US 9320796
Methods and compositions for self-regulated release of active pharmaceutical ingredient
Methods and compositions for self-regulated release of active pharmaceutical ingredient
Patent details — US 9320796
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 26, 2016
- Expiration
- Apr 21, 2036
- Applicant
- Acurx Pharmaceuticals, Inc.
- Claims
- 7
- CPC classes
- A61K, A61K31/5517, A61K47/02, A61K47/32
Quick answer
US 9320796 (Methods and compositions for self-regulated release of active pharmaceutical ingredient) is held by Acurx Pharmaceuticals, Inc.. Status: granted. Granted Apr 26, 2016. Expires Apr 21, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Acurx Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 7
- CPC classes
- A61K, A61K31/5517, A61K47/02, A61K47/32, A61K9/2009, A61K9/2027
More from Acurx Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12036225
Use of ibezapolstat to promote microbiome health
granted -
US 11857629
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11723885
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11554114
Methods and compositions for self-regulated release of active pharmaceutical ingredients
granted -
US 11197837
Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse
granted -
US 11103581
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11083794
Methods and compositions for self-regulated release of active pharmaceutical ingredient
granted -
US 11001592
DNA polymerase IIIC inhibitors and use thereof
granted
Frequently asked questions
What is US patent 9320796?
US 9320796 (Methods and compositions for self-regulated release of active pharmaceutical ingredient) is held by Acurx Pharmaceuticals, Inc.. Status: granted. Granted Apr 26, 2016. Expires Apr 21, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9320796?
Acurx Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 28 pharmaceutical patents for this assignee.
When does US 9320796 expire?
Our index shows an expiration date of Apr 21, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.